High expression of microRNA-155 is associated with the aggressive malignant behavior of gallbladder carcinoma.

Hiroshi Kono, Masafumi Nakamura, Takao Ohtsuka, Yosuke Nagayoshi, Yasuhisa Mori, Shunichi Takahata, Shinichi Aishima, Masao Tanaka

研究成果: ジャーナルへの寄稿記事

39 引用 (Scopus)

抄録

The prognosis of gallbladder cancer (GBC) remains poor despite recent advances in diagnostics and therapeutic strategies. Although the role of microRNAs (miRs) in GBC have not been well documented, miR-155 is known to be associated with inflammation-associated carcinogenesis in various types of cancers. The aim of this study was to investigate the clinical significance of miR-155 expression and the biological functions of miR-155 in GBC. The expression levels of miR-155 in surgically resected GBCs and gallbladders with pancreaticobiliary maljunction (PBM) were assessed by quantitative reverse transcription-polymerase chain reaction. The relationship between the expression levels of miR-155 and clinicopathological features of GBCs was analyzed. Human GBC cell lines were transfected with miR-155 inhibitors or mimics, and the effects on proliferation and invasion were assessed. miR-155 was significantly overexpressed in GBCs when compared with that in gallbladders with PBM (p=0.007) and normal gallbladders (p=0.04). The high expression level of miR-155 in GBCs was significantly associated with the presence of lymph node metastasis (p=0.01) and a poor prognosis (p=0.02). In vitro assays showed that aberrant expression of miR-155 significantly enhanced GBC cell proliferation and invasion. In conclusion, high miR-155 expression correlates with the aggressive behavior of GBCs, and miR-155 may become a prognostic marker and therapeutic target for GBC.

元の言語英語
ページ(範囲)17-24
ページ数8
ジャーナルOncology reports
30
発行部数1
DOI
出版物ステータス出版済み - 7 2013

Fingerprint

Gallbladder Neoplasms
Gallbladder
MicroRNAs
Carcinoma
Reverse Transcription
Carcinogenesis
Lymph Nodes
Cell Proliferation
Neoplasm Metastasis
Inflammation
Cell Line
Polymerase Chain Reaction
Therapeutics
Neoplasms

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

これを引用

High expression of microRNA-155 is associated with the aggressive malignant behavior of gallbladder carcinoma. / Kono, Hiroshi; Nakamura, Masafumi; Ohtsuka, Takao; Nagayoshi, Yosuke; Mori, Yasuhisa; Takahata, Shunichi; Aishima, Shinichi; Tanaka, Masao.

:: Oncology reports, 巻 30, 番号 1, 07.2013, p. 17-24.

研究成果: ジャーナルへの寄稿記事

Kono, Hiroshi ; Nakamura, Masafumi ; Ohtsuka, Takao ; Nagayoshi, Yosuke ; Mori, Yasuhisa ; Takahata, Shunichi ; Aishima, Shinichi ; Tanaka, Masao. / High expression of microRNA-155 is associated with the aggressive malignant behavior of gallbladder carcinoma. :: Oncology reports. 2013 ; 巻 30, 番号 1. pp. 17-24.
@article{f26f6b4f892148e8aeabcebde7ea33a3,
title = "High expression of microRNA-155 is associated with the aggressive malignant behavior of gallbladder carcinoma.",
abstract = "The prognosis of gallbladder cancer (GBC) remains poor despite recent advances in diagnostics and therapeutic strategies. Although the role of microRNAs (miRs) in GBC have not been well documented, miR-155 is known to be associated with inflammation-associated carcinogenesis in various types of cancers. The aim of this study was to investigate the clinical significance of miR-155 expression and the biological functions of miR-155 in GBC. The expression levels of miR-155 in surgically resected GBCs and gallbladders with pancreaticobiliary maljunction (PBM) were assessed by quantitative reverse transcription-polymerase chain reaction. The relationship between the expression levels of miR-155 and clinicopathological features of GBCs was analyzed. Human GBC cell lines were transfected with miR-155 inhibitors or mimics, and the effects on proliferation and invasion were assessed. miR-155 was significantly overexpressed in GBCs when compared with that in gallbladders with PBM (p=0.007) and normal gallbladders (p=0.04). The high expression level of miR-155 in GBCs was significantly associated with the presence of lymph node metastasis (p=0.01) and a poor prognosis (p=0.02). In vitro assays showed that aberrant expression of miR-155 significantly enhanced GBC cell proliferation and invasion. In conclusion, high miR-155 expression correlates with the aggressive behavior of GBCs, and miR-155 may become a prognostic marker and therapeutic target for GBC.",
author = "Hiroshi Kono and Masafumi Nakamura and Takao Ohtsuka and Yosuke Nagayoshi and Yasuhisa Mori and Shunichi Takahata and Shinichi Aishima and Masao Tanaka",
year = "2013",
month = "7",
doi = "10.3892/or.2013.2443",
language = "English",
volume = "30",
pages = "17--24",
journal = "Oncology Reports",
issn = "1021-335X",
publisher = "Spandidos Publications",
number = "1",

}

TY - JOUR

T1 - High expression of microRNA-155 is associated with the aggressive malignant behavior of gallbladder carcinoma.

AU - Kono, Hiroshi

AU - Nakamura, Masafumi

AU - Ohtsuka, Takao

AU - Nagayoshi, Yosuke

AU - Mori, Yasuhisa

AU - Takahata, Shunichi

AU - Aishima, Shinichi

AU - Tanaka, Masao

PY - 2013/7

Y1 - 2013/7

N2 - The prognosis of gallbladder cancer (GBC) remains poor despite recent advances in diagnostics and therapeutic strategies. Although the role of microRNAs (miRs) in GBC have not been well documented, miR-155 is known to be associated with inflammation-associated carcinogenesis in various types of cancers. The aim of this study was to investigate the clinical significance of miR-155 expression and the biological functions of miR-155 in GBC. The expression levels of miR-155 in surgically resected GBCs and gallbladders with pancreaticobiliary maljunction (PBM) were assessed by quantitative reverse transcription-polymerase chain reaction. The relationship between the expression levels of miR-155 and clinicopathological features of GBCs was analyzed. Human GBC cell lines were transfected with miR-155 inhibitors or mimics, and the effects on proliferation and invasion were assessed. miR-155 was significantly overexpressed in GBCs when compared with that in gallbladders with PBM (p=0.007) and normal gallbladders (p=0.04). The high expression level of miR-155 in GBCs was significantly associated with the presence of lymph node metastasis (p=0.01) and a poor prognosis (p=0.02). In vitro assays showed that aberrant expression of miR-155 significantly enhanced GBC cell proliferation and invasion. In conclusion, high miR-155 expression correlates with the aggressive behavior of GBCs, and miR-155 may become a prognostic marker and therapeutic target for GBC.

AB - The prognosis of gallbladder cancer (GBC) remains poor despite recent advances in diagnostics and therapeutic strategies. Although the role of microRNAs (miRs) in GBC have not been well documented, miR-155 is known to be associated with inflammation-associated carcinogenesis in various types of cancers. The aim of this study was to investigate the clinical significance of miR-155 expression and the biological functions of miR-155 in GBC. The expression levels of miR-155 in surgically resected GBCs and gallbladders with pancreaticobiliary maljunction (PBM) were assessed by quantitative reverse transcription-polymerase chain reaction. The relationship between the expression levels of miR-155 and clinicopathological features of GBCs was analyzed. Human GBC cell lines were transfected with miR-155 inhibitors or mimics, and the effects on proliferation and invasion were assessed. miR-155 was significantly overexpressed in GBCs when compared with that in gallbladders with PBM (p=0.007) and normal gallbladders (p=0.04). The high expression level of miR-155 in GBCs was significantly associated with the presence of lymph node metastasis (p=0.01) and a poor prognosis (p=0.02). In vitro assays showed that aberrant expression of miR-155 significantly enhanced GBC cell proliferation and invasion. In conclusion, high miR-155 expression correlates with the aggressive behavior of GBCs, and miR-155 may become a prognostic marker and therapeutic target for GBC.

UR - http://www.scopus.com/inward/record.url?scp=84883615570&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883615570&partnerID=8YFLogxK

U2 - 10.3892/or.2013.2443

DO - 10.3892/or.2013.2443

M3 - Article

C2 - 23660842

AN - SCOPUS:84883615570

VL - 30

SP - 17

EP - 24

JO - Oncology Reports

JF - Oncology Reports

SN - 1021-335X

IS - 1

ER -